Internal medicine, Glioma, Cancer research, Oncology and Surgery are his primary areas of study. His Internal medicine and Clinical trial, Phases of clinical research, Temozolomide, Survival rate and Randomized controlled trial investigations all form part of his Internal medicine research activities. His Glioma study combines topics from a wide range of disciplines, such as Proliferation index, Progression-free survival, Antigen-presenting cell and Brain tumor, Pathology.
The concepts of his Cancer research study are interwoven with issues in Cancer, Epidermal growth factor receptor, Protein kinase B, Immunology and PTEN. His Oncology research is multidisciplinary, incorporating elements of Central nervous system disease, Radiation therapy, Toxicity and Chemotherapy. His work in Surgery addresses subjects such as Hazard ratio, which are connected to disciplines such as Proportional hazards model.
His primary scientific interests are in Internal medicine, Oncology, Glioma, Cancer research and Bevacizumab. He interconnects Surgery and Glioblastoma in the investigation of issues within Internal medicine. His Oncology research integrates issues from Clinical trial, Proportional hazards model and Chemotherapy.
His research integrates issues of Cancer, Mutant, IDH1, Pathology and Magnetic resonance imaging in his study of Glioma. His work deals with themes such as PI3K/AKT/mTOR pathway, Protein kinase B, Signal transduction, Epidermal growth factor receptor and Immunology, which intersect with Cancer research. As part of the same scientific family, Timothy F. Cloughesy usually focuses on Bevacizumab, concentrating on Nuclear medicine and intersecting with Effective diffusion coefficient.
Timothy F. Cloughesy mainly focuses on Internal medicine, Glioma, Oncology, Cancer research and Glioblastoma. Internal medicine is a component of his Bevacizumab, Phases of clinical research, Temozolomide, Recurrent glioblastoma and Clinical trial studies. His Glioma study integrates concerns from other disciplines, such as Pharmacokinetics, Mutant, Immune system, Magnetic resonance imaging and Proportional hazards model.
As a part of the same scientific study, Timothy F. Cloughesy usually deals with the Oncology, concentrating on Adverse effect and frequently concerns with Gastroenterology. His Cancer research study combines topics in areas such as Phenotype, Cancer, DNA methylation and In vivo. His biological study spans a wide range of topics, including Brain tumor, Combined Modality Therapy and Medical physics.
The scientist’s investigation covers issues in Internal medicine, Oncology, Glioma, Glioblastoma and Clinical trial. His research brings together the fields of Gastroenterology and Internal medicine. His Oncology research includes themes of Survival rate, Biomarker, Magnetic resonance imaging and Radiation therapy.
Glioma is a subfield of Cancer research that Timothy F. Cloughesy investigates. His study looks at the intersection of Glioblastoma and topics like Newly diagnosed with Dendritic cell vaccine and Placebo. His Clinical trial research incorporates elements of O-6-methylguanine-DNA methyltransferase and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen.
Journal of Clinical Oncology (2009)
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot;Wolfgang Wick;Warren Mason;Roger Henriksson.
The New England Journal of Medicine (2014)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Ingo K. Mellinghoff;Maria Y. Wang;Igor Vivanco;Daphne A. Haas-Kogan.
The New England Journal of Medicine (2005)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Rameen Beroukhim;Gad Getz;Leia Nghiemphu;Jordi Barretina.
Proceedings of the National Academy of Sciences of the United States of America (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler.
Nature Genetics (2007)
Gene Expression Profiling of Gliomas Strongly Predicts Survival
William A. Freije;F. Edmundo Castro-Vargas;Zixing Fang;Steve Horvath.
Cancer Research (2004)
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target
S. Horvath;B. Zhang;M. Carlson;K. V. Lu.
Proceedings of the National Academy of Sciences of the United States of America (2006)
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
Tim F Cloughesy;Koji Yoshimoto;Phioanh Leia Nghiemphu;Kevin Brown.
PLOS Medicine (2008)
Analysis of the Phosphatidylinositol 3′-Kinase Signaling Pathway in Glioblastoma Patients in Vivo
Gheeyoung Choe;Steve Horvath;Timothy F. Cloughesy;Katherine Crosby.
Cancer Research (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: